India, March 24 -- Gilead Sciences Inc. (GILD), on Monday, entered into a definitive agreement to acquire privately held Ouro Medicines.
The deal includes $1.675 billion in upfront cash, with up to $500 million in additional milestone payments, and aims to strengthen the company's inflammation and autoimmune disease portfolio.
The acquisition adds OM336 or gamgertamig, a clinical-stage BCMAxCD3 T cell engager designed for rapid and deep B cell depletion following a limited treatment course.
The therapy is currently being evaluated in Phase 1/2 studies for autoimmune hemolytic anemia and immune thrombocytopenia, with plans to enter registrational studies in 2027.
The company said OM336 has shown strong early efficacy and a differentiated...